Over the next three years, Immunovia and its partners will use the firm's Immray PanCan-d assay to screen 6,000 diabetes patients for pancreatic cancer.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
SMiLE-seq combines antibody arrays, mechanical trapping, and next-generation sequencing readouts to provide a new platform for characterizing DNA-protein interactions.
The study, called Panfam-1, will analyze 1,000 individuals at high risk of familial pancreatic cancer over three years using the company's antibody array test.
Translational scientist Jacqueline Achkar of Albert Einstein Medical College will lead several collaborations to build a point-of-care diagnostic platform.
The firm is developing tests based on its microarray technology, which is capable of printing multiple types of biomarkers.
The Swedish firm, a spinout of Lund University, will evaluate the array-based blood tests to confirm, rule out, and monitor the autoimmune disease.
The microcapillary-based single-cell platform is designed to analyze antibodies but could be used to detect other cell products.
ImmunArray is launching the SLE-Key Rule Out test to exclude a diagnosis of lupus, a test run on its multiple-antigen microarray-based technology.
The approach could allow the use of antibody array tests in resource-poor areas where fluorescence detection systems are too expensive or difficult to maintain.
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.